The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Open accessAbstract
The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by cancer-associated fibroblasts of several tumor entities. Here, we quantify the tumor uptake on 68Ga-FAPI PET/CT of various primary and metastatic tumors to identify the most promising indications for future application. Methods:68Ga-FAPI PET/CT scans were requested by various referring physicians according to individual clinical indications that were considered insufficiently covered by 18F-FDG PET/CT or other imaging modalities. All PET/CT was performed 1 h after injection of 122–312 MBq of 68Ga-FAPI-04. We retrospectively identified 80 patients with histopathologically proven primary tumors or metastases or radiologically unequivocal metastatic lesions of histologically proven primary tumors. Tumor uptake was quantified by SUVmax and SUVmean (60% isocontour). Results: Eighty patients with 28 different tumor entities (54 primary tumors and 229 metastases) were evaluated. The highest average SUVmax (>12) was found in sarcoma, esophageal, breast, cholangiocarcinoma, and lung cancer. The lowest 68Ga-FAPI uptake (average SUVmax < 6) was observed in pheochromocytoma, renal cell, differentiated thyroid, adenoid cystic, and gastric cancer. The average SUVmax of hepatocellular, colorectal, head–neck, ovarian, pancreatic, and prostate cancer was intermediate (SUV 6–12). SUV varied across and within all tumor entities. Because of low background in muscle and blood pool (SUVmax < 2), the tumor-to-background contrast ratios were more than 3-fold in the intermediate and more than 6-fold in the high-intensity uptake group. Conclusion: Several highly prevalent cancers presented with remarkably high uptake and image contrast on 68Ga-FAPI PET/CT. The high and rather selective tumor uptake may open up new applications for noninvasive tumor characterization, staging examinations, or radioligand therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lindner, T., Loktev, A., Altmann, A., Giesel, F., Kratochwil, C., Debus, J., Jäger, D., Mier, W., & Haberkorn, U. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210443 · Cited by 935
Self-citationA Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts
Loktev, A., Lindner, T., Mier, W., Debus, J., Altmann, A., Jäger, D., Giesel, F., Kratochwil, C., Barthe, P., Roumestand, C., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210435 · Cited by 777
Self-citationGarin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Giesel, F. L., Kratochwil, C., Lindner, T., Marschalek, M. M., Loktev, A., Lehnert, W., Debus, J., Jäger, D., Flechsig, P., Altmann, A., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.215913 · Cited by 740
Self-citationDevelopment of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
Loktev, A., Lindner, T., Burger, E.-M., Altmann, A., Giesel, F., Kratochwil, C., Debus, J., Marmé, F., Jäger, D., Mier, W., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224469 · Cited by 554
Self-citationHamson, E. J., Keane, F. M., Tholen, S., Schilling, O., & Gorrell, M. D. (2014) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201300095 · Cited by 496
Kauhanen, S. P., Komar, G., Seppänen, M. P., Dean, K. I., Minn, H. R., Kajander, S. A., Rinta-Kiikka, I., Alanen, K., Borra, R. J., Puolakkainen, P. A., et al. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181b2fafa · Cited by 317
Welt, S., Divgi, C. R., Scott, A. M., Garin-Chesa, P., Finn, R. D., Graham, M., Carswell, E. A., Cohen, A., Larson, S. M., & Old, L. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.6.1193 · Cited by 266
Barrio, M., Czernin, J., Fanti, S., Ambrosini, V., Binse, I., Du, L., Eiber, M., Herrmann, K., & Fendler, W. P. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.185587 · Cited by 205
Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing
Afshar-Oromieh, A., Hetzheim, H., Kübler, W., Kratochwil, C., Giesel, F. L., Hope, T. A., Eder, M., Eisenhut, M., Kopka, K., & Haberkorn, U. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3419-0 · Cited by 185
Self-citation89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
Pandit-Taskar, N. D., O’Donoghue, J. A., Beylergil, V., Lyashchenko, S. K., Ruan, S., Solomon, S. B., Durack, J. C., Carrasquillo, J. A., Lefkowitz, R. A., Gönen, M., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2830-7 · Cited by 156
Antwi, K., Fani, M., Heye, T., Nicolas, G., Rottenburger, C., Kaul, F., Merkle, E., Zech, C. J., Boll, D., Vogt, D. R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4101-5 · Cited by 124
18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging
Caresia-Aróztegui, A. P., Vicente, A. M. G., Ruiz, S. Á., Bolton, R. C. D., Rincón, J. O., Garzón, J. R. G., Torres, M. D. A., & García‐Velloso, M. J. (2017) · Tumor Biology · doi:10.1177/1010428317728285 · Cited by 89
Jiang, C., Chen, Y., Zhu, Y., & Xu, Y. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.10.57 · Cited by 73
Fibroblast-Activating Protein: Targeting the Roots of the Tumor Microenvironment
Siveke, J. T. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.214361 · Cited by 69
Parghane, R. V., & Basu, S. K. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2017.02.009 · Cited by 65
Plaxton, N. A., Brandon, D. C., Corey, A. S., Harrison, C. E., Kendi, A. T. K., HALKAR, R. K., & Barron, B. J. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.14.12828 · Cited by 54
FDG-PET is not useful in early pancreatic cancer diagnosis
Strobel, O., & Büchler, M. W. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.42 · Cited by 52
Paudyal, B., Oriuchi, N., Paudyal, P., Tsushima, Y., Higuchi, T., Miyakubo, M., Ishikita, T., Nakajima, T., & Endo, K. (2008) · Annals of Nuclear Medicine · doi:10.1007/s12149-007-0076-1 · Cited by 47
Davidson, B., Goldberg, I., & Kopolovic, J. (1997) · Pathology - Research and Practice · doi:10.1016/s0344-0338(97)80102-1 · Cited by 46
Present and future of FDG-PET/CT in ovarian cancer
Kitajima, K., Murakami, K., Sakamoto, S., Kaji, Y., & Sugimura, K. (2010) · Annals of Nuclear Medicine · doi:10.1007/s12149-010-0449-8 · Cited by 45
Tagliabue, L., & Sole, A. D. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.06.012 · Cited by 41
PET/MRI and PET/CT in Lung Lesions and Thoracic Malignancies
Flechsig, P., Mehndiratta, A., Haberkorn, U., Kratochwil, C., & Giesel, F. L. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.03.004 · Cited by 37
Self-citationAmodru, V., Guérin, C., Delcourt, S., Romanet, P., Loundou, A., Viana, B., Brue, T. C., Castinetti, F., Sebag, F. A., Pacák, K., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3833-y · Cited by 37
Cited by
Chen, H., Pang, Y., Wu, J., Zhao, L., Hao, B., Wu, J., Wei, J., Wu, S., Zhao, L., Luo, Z., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04769-z · Cited by 545
Zhang, H., Yue, X., Chen, Z., Liu, C., Wu, W., Zhang, N., Liu, Z., Yang, L., Jiang, Q., Cheng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01860-5 · Cited by 424
Baum, R. P., Schuchardt, C., Singh, A., Chantadisai, M., Robiller, F. C., Zhang, J., Mueller, D., Eismant, A., Almaguel, F., Zboralski, D., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.259192 · Cited by 359
Advances in PET imaging of cancer
Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H.-G., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 312
Watabe, T., Liu, Y., Kaneda-Nakashima, K., Shirakami, Y., Lindner, T., Ooe, K., Toyoshima, A., Nagata, K., Shimosegawa, E., Haberkorn, U., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233122 · Cited by 302
Self-citation
Metadata
- Authors
- Kratochwil, C., Flechsig, P., Lindner, T., Abderrahim, L., Altmann, A., Mier, W., Adeberg, S., Rathke, H., Röhrich, M., Winter, H., Plinkert, P. K., Marme, F., Lang, M., Kauczor, H.-U., Jäger, D., Debus, J., Haberkorn, U., & Giesel, F. L.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2019-04-06
- Volume
- 60
- Issue
- 6
- Pages
- 801-805
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2930582547
- Cited by
- 1,464
- References
- 24
- FWCI
- 52.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.